Immunotherapy Innovations in the Fight Against Osteosarcoma: Emerging Strategies and Promising Progress

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Feb 24

PMID 38399305

Authors

Shigao Cheng

Huiyuan Wang

Xuejia Kang

Hui Zhang

Affiliations

Soon will be listed here.

Abstract

Immunosuppressive elements within the tumor microenvironment are the primary drivers of tumorigenesis and malignant advancement. The presence, as well as the crosstalk between myeloid-derived suppressor cells (MDSCs), osteosarcoma-associated macrophages (OS-Ms), regulatory T cells (Tregs), and endothelial cells (ECs) with osteosarcoma cells cause the poor prognosis of OS. In addition, the consequent immunosuppressive factors favor the loss of treatment potential. Nanoparticles offer a means to dynamically and locally manipulate immuno-nanoparticles, which present a promising strategy for transforming OS-TME. Additionally, chimeric antigen receptor (CAR) technology is effective in combating OS. This review summarizes the essential mechanisms of immunosuppressive cells in the OS-TME and the current immune-associated strategies. The last part highlights the limitations of existing therapies and offers insights into future research directions.

Citing Articles

New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.

Luo C, Min X, Zhang D Front Immunol. 2025; 15:1539696.

PMID: 39896817 PMC: 11782189. DOI: 10.3389/fimmu.2024.1539696.

The role of neutrophils in osteosarcoma: insights from laboratory to clinic.

Xia M, Han Y, Sun L, Li D, Zhu C, Li D Front Immunol. 2024; 15:1490712.

PMID: 39582869 PMC: 11582048. DOI: 10.3389/fimmu.2024.1490712.

Single-cell RNA sequencing reveals the communications between tumor microenvironment components and tumor metastasis in osteosarcoma.

Li J, Bai Y, Zhang H, Chen T, Shang G Front Immunol. 2024; 15:1445555.

PMID: 39324133 PMC: 11422128. DOI: 10.3389/fimmu.2024.1445555.

Identification of a novel cellular senescence-related lncRNA signature for prognosis and immune response in osteosarcoma.

Wu H, Deng C, Zheng X, Huang Y, Chen C, Gu H Transl Cancer Res. 2024; 13(7):3742-3759.

PMID: 39145087 PMC: 11319968. DOI: 10.21037/tcr-24-163.

LncRNA HOXA-AS3 promotes cell proliferation and invasion via targeting miR-218-5p/FOXP1 axis in osteosarcoma.

Li R, Chen P, Zhou Y, Lang Y, Zhou C, Ren J Sci Rep. 2024; 14(1):16581.

PMID: 39019995 PMC: 11254915. DOI: 10.1038/s41598-024-67596-4.

References

Yu W, Wang Y, Zhu J, Jin L, Liu B, Xia K . Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy. Biomaterials. 2018; 192:128-139. DOI: 10.1016/j.biomaterials.2018.11.019. View

Young A, Mittal D, Stagg J, Smyth M . Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014; 4(8):879-88. DOI: 10.1158/2159-8290.CD-14-0341. View

Cascini C, Chiodoni C . The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response. Cells. 2021; 10(7). PMC: 8304628. DOI: 10.3390/cells10071668. View

Wu K, Lin K, Li X, Yuan X, Xu P, Ni P . Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. Front Immunol. 2020; 11:1731. PMC: 7417513. DOI: 10.3389/fimmu.2020.01731. View

Katz J, Muller A, Prendergast G . Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008; 222:206-21. DOI: 10.1111/j.1600-065X.2008.00610.x. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Li Y, Rezvani K, Rafei H . Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer. Immunol Rev. 2023; 320(1):217-235. PMC: 10841677. DOI: 10.1111/imr.13255. View

Nirala B, Yamamichi T, Petrescu D, Shafin T, Yustein J . Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis. Cancers (Basel). 2023; 15(20). PMC: 10605493. DOI: 10.3390/cancers15205108. View

Gargett T, Yu W, Dotti G, Yvon E, Christo S, Hayball J . GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 2016; 24(6):1135-1149. PMC: 4923328. DOI: 10.1038/mt.2016.63. View

10.

Lin Z, Wu Z, Luo W . Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma. Cancers (Basel). 2021; 13(17). PMC: 8431424. DOI: 10.3390/cancers13174469. View

11.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

12.

Deng X, Liang H, Yang W, Shao Z . Polarization and function of tumor-associated macrophages mediate graphene oxide-induced photothermal cancer therapy. J Photochem Photobiol B. 2020; 208:111913. DOI: 10.1016/j.jphotobiol.2020.111913. View

13.

Mota J, Leite C, Souza L, Melo P, Nascimento D, de-Deus-Wagatsuma V . Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice. Cancer Immunol Res. 2016; 4(4):312-22. DOI: 10.1158/2326-6066.CIR-15-0170. View

14.

Zajac A, Czarnecka A, Rutkowski P . The Role of Macrophages in Sarcoma Tumor Microenvironment and Treatment. Cancers (Basel). 2023; 15(21). PMC: 10648209. DOI: 10.3390/cancers15215294. View

15.

Guo F, Feng Y, Zhao G, Zhang R, Cheng Z, Kong W . Tumor-Associated CD163 M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer. Cancer Manag Res. 2020; 12:5831-5843. PMC: 7369418. DOI: 10.2147/CMAR.S257692. View

16.

Azimnasab-Sorkhabi P, Soltani-Asl M, Kfoury Junior J . Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells. Hum Cell. 2023; 36(4):1225-1232. DOI: 10.1007/s13577-023-00893-8. View

17.

Kopecka J, Campia I, Brusa D, Doublier S, Matera L, Ghigo D . Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med. 2010; 15(7):1492-504. PMC: 3823194. DOI: 10.1111/j.1582-4934.2010.01137.x. View

18.

Barani M, Mukhtar M, Rahdar A, Sargazi S, Pandey S, Kang M . Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma. Biosensors (Basel). 2021; 11(2). PMC: 7924594. DOI: 10.3390/bios11020055. View

19.

Xu W, Hiu T, Malarkannan S, Wang L . The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol. 2018; 15(5):438-446. PMC: 6068175. DOI: 10.1038/cmi.2017.148. View

20.

Sheth V, Gauthier J . Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2020; 56(3):552-566. PMC: 8592274. DOI: 10.1038/s41409-020-01134-4. View